Filgotinib versus steroid injection bridging in newly diagnosed rheumatoid arthritis
Compares filgotinib tablets with a steroid injection to bridge early rheumatoid arthritis treatment.
Key facts
- Who runs it
- Medisch Spectrum Twente
- Where
- Enschede, NetherlandsSee the site
- Trial code
- Registry title
- Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 168 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional
- Record updated
- 16 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed rheumatoid arthritis who have never taken disease-modifying drugs (DMARDs). It compares two short-term treatments given at the start of methotrexate and hydroxychloroquine therapy.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed rheumatoid arthritis, diagnosed by a rheumatologist, with a DAS28-CRP score above 2.6 at the start.
- Earlier treatment
- Must never have taken DMARDs. No corticosteroids in the last three months.
Main reasons for not taking part
- Current or earlier treatment with DMARDs
- Risk of cardiovascular disease
- Risk of cancer, including current or long-term smoking
- Pregnancy, planned pregnancy or planning to father a child
- Corticosteroid use in the last three months
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Newly diagnosed rheumatoid arthritis patients according to a rheumatologist
- DMARD-naive
- Age 18 – 64 years old
- DAS28-CRP > 2.6 at the start of the study
- Dutch proficiency
- Signed informed consent
Who cannot take part
- Current or prior treatment with DMARDs
- Corticosteroid use in the last three months
- Risk of cardiovascular diseases
- Risk of malignancies, including current smoking of having smoked for a long time
- (Planned) pregnancy or planning to father a child
- Contra-indications for methotrexate, adalimumab, tocilizumab, hydroxychloroquine, triamcinolone, filgotinib or folic acid (protocol section 4.3)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Medisch Spectrum TwenteEnschede, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To investigate non-inferiority and potential superiority in achieving disease activity remission at 3 months of bridging with a JAK inhibitor (Filgotinib 200 mg once daily for 3 months) versus bridging with corticosteroids (triamcinolone 120 mg single dose im) when starting with methotrexate and hydroxychloroquine therapy in rheumatoid arthritis patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
- Plain-language title
- Filgotinib versus steroid injection bridging in newly diagnosed rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-517112-30-00, who can take part
- Record updated
- 16 January 2025